Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815192 | 0.82 | — | — | |
| SCHEMBL252560 | 0.82 | CYP2C19 (0.44) | CYP2C19 | |
| SCHEMBL5206311 | 0.79 | CYP2C19 (0.35) | CYP2C19ALDH1A1CYP4F2CYP4A11HSD17B10 | |
| SCHEMBL18095993 | 0.79 | CYP2C19 (0.61) | CYP2C19ALDH1A1CYP4F2CYP4A11HSD17B10 | |
| SCHEMBL2655881 | 0.79 | KDM4E (0.34) | DPP4 | |
| SCHEMBL5546369 | 0.79 | CYP2C19 (0.35) | CYP2C19ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL13804310 | 0.79 | SMN1; SMN2 (0.32) | DPP4 | |
| SCHEMBL27504849 | 0.79 | CYP2C19 (0.35) | CYP2C19ALDH1A1CYP4F2CYP4A11HSD17B10 | |
| SCHEMBL6639755 | 0.79 | MME (0.37) | CYP2C19ALDH1A1CYP4F2CYP4A11HSD17B10 | |
| SCHEMBL1971456 | 0.79 | CYP2C19 (0.35) | CYP2C19ALDH1A1CYP4F2CYP4A11HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-112689507-B | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3490974-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2023-12-06 | — | — | EP | disclosed |
| CN-109906218-B | Spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-11512051-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-01-06 | — | — | US | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| EP-1932840-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-18 | — | — | EP | disclosed |
| CN-1177821-C | Matrix metalloprotease inhibitors | - | 2004-12-01 | — | — | CN | disclosed |
| EP-1217002-B1 | 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors | SERVIER LAB (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| EP-1217002-A1 | 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors | Les Laboratoires Servier (FR) | 2002-06-26 | — | — | EP | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| CN-1160045-A | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 1997-09-24 | — | — | CN | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | CYP2C19 4347/4885ALDH1A1 2694/4885CYP4F2 4794/4885 |
| US-11512051-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CYP2C19 1267/4885ALDH1A1 2489/4885CYP4F2 2855/4885 |
| US-20080182842-A1 | L-alanine derivatives as a5beta1 antagonists | ITGB1, ITGA2B, ITGB5 | CYP2C19 4749/4885ALDH1A1 345/4885CYP4F2 4591/4885 |
| US-20220002242-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CYP2C19 1267/4885ALDH1A1 2489/4885CYP4F2 2855/4885 |
| US-20240294520-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | CYP2C19 4347/4885ALDH1A1 2694/4885CYP4F2 4794/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | CYP2C19 4347/4885ALDH1A1 2694/4885CYP4F2 4794/4885 |
| US-20220289743-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | ITGA2B, ITGB6, ITGB1 | CYP2C19 4347/4885ALDH1A1 2694/4885CYP4F2 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.